Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2007

01-10-2007 | Breast Oncology

Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation

Authors: Erika A. Newman, MD, Michael S. Sabel, MD, Alexis V. Nees, MD, Anne Schott, MD, Kathleen M. Diehl, MD, Vincent M. Cimmino, MD, Alfred E. Chang, MD, Celina Kleer, MD, Daniel F. Hayes, MD, Lisa A. Newman, MD, MPH

Published in: Annals of Surgical Oncology | Issue 10/2007

Login to get access

Abstract

Background

The optimal strategy for incorporating lymphatic mapping and sentinel lymph node biopsy into the management of breast cancer patients receiving neoadjuvant chemotherapy remains controversial. Previous studies of sentinel node biopsy performed following neoadjuvant chemotherapy have largely reported on patients whose prechemotherapy, pathologic axillary nodal status was unknown. We report findings using a novel comprehensive approach to axillary management of node-positive-patients receiving neoadjuvant chemotherapy.

Methods

We evaluated 54 consecutive breast cancer patients with biopsy-proven axillary nodal metastases at the time of diagnosis that underwent lymphatic mapping with nodal biopsy as well as concomitant axillary lymph node dissection after receiving neoadjuvant chemotherapy. All cases were treated at a single comprehensive cancer center between 2001 and 2005.

Results

The sentinel node identification rate after delivery of neoadjuvant chemotherapy was 98%. Thirty-six patients (66%) had residual axillary metastases (including eight patients that had undergone resection of metastatic sentinel nodes at the time of diagnosis), and in 12 cases (31%) the residual metastatic disease was limited to the sentinel lymph node. The final, post-neoadjuvant chemotherapy sentinel node was falsely negative in three cases (8.6%). The negative final sentinel node accurately identified patients with no residual axillary disease in 17 cases (32%).

Conclusions

Sentinel lymph node biopsy performed after the delivery of neoadjuvant chemotherapy in patients with documented nodal disease at presentation accurately identified cases that may have been downstaged to node-negative status and can spare this subset of patients (32%) from experiencing the morbidity of an axillary dissection.
Literature
1.
Lyman GH, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23(30):7703–20PubMedCrossRef
2.
Giuliano AE, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220(3):391–8; discussion 398–401PubMedCrossRef
3.
Krag DN, et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2(6):335–9; discussion 340PubMedCrossRef
4.
Albertini JJ, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276(22):1818–22PubMedCrossRef
5.
Breslin TM, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000; 18(20):3480–6PubMed
6.
Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003; 83(4):931–42PubMedCrossRef
7.
Balch GC, et al. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 2003; 10(6):616–21PubMedCrossRef
8.
Nason KS, et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000; 89(11):2187–94PubMedCrossRef
9.
Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 2001; 182(4):312–5PubMedCrossRef
10.
Reitsamer R, et al. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol 2003; 84(2):63–7PubMedCrossRef
11.
Fernandez A, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001; 22(4):361–6PubMedCrossRef
12.
Brady E. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 2002; 8(2):97–100PubMedCrossRef
13.
Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 2003; 9(5):374–9PubMedCrossRef
14.
Stearns V, et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002; 9(3):235–42PubMedCrossRef
15.
Sabel MS, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003; 186(2):102–5PubMedCrossRef
16.
Khan A, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol 2005; 12(9):697–704PubMedCrossRef
17.
National Comprehensive Cancer Network Practice Guidelines in Oncology, Vol. 2, Jenkintown, PA: National Comprehensive Cancer Network, 2006, BINV-10
18.
Fisher B, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16(8):2672–85PubMed
19.
Wolmark N, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 30:96–102PubMed
20.
Mamounas E, et al. Accuracy of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: Updated results from NSABP B-27 (abstract No. 140). American Society of Clinical Oncology 38th Annual Meeting 2002; Orlando, FL
21.
Krag D, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998; 339(14):941–6PubMedCrossRef
22.
Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006; 106(1):4–16PubMedCrossRef
23.
Cox CE, et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol 2006; 13(4):483–90PubMedCrossRef
24.
van Rijk MC, et al. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. Ann Surg Oncol 2006; 13(4):475–9PubMedCrossRef
25.
Ollila DW, et al. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg 2005; 190(3):371–5PubMedCrossRef
26.
Hennessy BT, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005; 23(36):9304–11PubMedCrossRef
27.
Gonzalez-Angulo AM, et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 2005; 23(28):7098–104PubMedCrossRef
28.
Huang EH, et al. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62(2):351–7PubMedCrossRef
29.
Rouzier R, et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 2002; 20(5):1304–10PubMedCrossRef
30.
Cody HS 3rd, Reoperative sentinel lymph node biopsy: adding nuance to the management of locally recurrent breast cancer. Ann Surg Oncol July 2006
31.
Port ER, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg 2002; 195(2):167–72PubMedCrossRef
32.
Krishnamurthy S, et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 2002; 95(5):982–8PubMedCrossRef
33.
Alvarez S, et al. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006; 186(5):1342–8PubMedCrossRef
34.
Damera A, et al. Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. Br J Cancer 2003; 89(7):1310–3PubMedCrossRef
35.
Kuenen-Boumeester V, et al. Ultrasound-guided fine needle aspiration cytology of axillary lymph nodes in breast cancer patients. A preoperative staging procedure. Eur J Cancer 2003; 39(2):170–4PubMedCrossRef
Metadata
Title
Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation
Authors
Erika A. Newman, MD
Michael S. Sabel, MD
Alexis V. Nees, MD
Anne Schott, MD
Kathleen M. Diehl, MD
Vincent M. Cimmino, MD
Alfred E. Chang, MD
Celina Kleer, MD
Daniel F. Hayes, MD
Lisa A. Newman, MD, MPH
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9403-y

Other articles of this Issue 10/2007

Annals of Surgical Oncology 10/2007 Go to the issue

Gastrointestinal Oncology

Young Age Influences Treatment but not Outcome of Colon Cancer

Breast Oncology

Mechanisms of HER2-Induced Endothelial Cell Retraction

Melanomas

Pelvic Lymph Node Dissection Is Beneficial in Subsets of Patients with Node-positive Melanoma

Endocrine Tumors

Outcomes of Pheochromocytoma Management in the Laparoscopic Era

OriginalPaper

Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Bone and Soft Tissue Sarcomas

Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated?